13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002785-20-DE
(EUCTR)
19/09/201111/08/2011Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple SclerosisEfficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis - EVIDIMS Multiple Sclerosis and Clinical isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Vigantol® Öl 20.000 I.E./ml
Product Name: Vigantol® Öl 20.000 I.E./ml
Product Code: Vigantol® Öl 20.000 I.E./ml
INN or Proposed INN: COLECALCIFEROL
Trade Name: Dekristol®-Tablette 1 (400 IE)
Product Name: Dekristol® 400-Tabletten
Product Code: Dekristol® 400-Tabletten
INN or Proposed INN: COLECALCIFEROL
Other descriptive name: 25OH-Vitamin D
Charité - Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany